Supplemental data for the manuscript: Targeting tumor hypoxia inhibits aggressive phenotype of dedifferentiated thyroid cancer

Supplementary materials <br> Table S1. Hypoxia signatures, IFN-γ signature and expanded immune gene signature Table S2. Sequences for siRNA of HIF1A and the primers Table S3. Antibodies used in this study Table S4. Clinicopathological characteristics and genetic alterations of PTC patients in the TCGA cohort Table S5. Clinicopathological characteristics and genetic alterations of DDTC patients in the GSE76039 cohort Fig. S1 Forest plots showed hypoxia score’s correlations with overall survival in pan-cancer analyses. Fig. S2 Gene set enrichment analyses were performed to identify therapy-associated signaling pathways enriched in 74 DDTC patients from the combined GEO cohort. Fig. S3 The associations of hypoxia score with thyroid differentiation score (TDS), immune-checkpoint markers, tumor-associated macrophage markers and cancer-associated fibroblast markers in PTC patients from the TCGA cohort. Fig. S4 Analyses of HIF1α expression’s correlations with PDL1/CD274 and PDL2/PDCD1LG2 in the TCGA cohort (A and B) and the combined GEO cohort (C).